Premium Nahrungsergänzungsmittel | artgerecht

Atovaquone-Proguanil: Malaria Prevention and Treatment

Atovaquone-proguanil is a combination medication used to prevent and treat malaria. It is commonly recommended for travelers visiting malaria-endemic regions.

Regular tips about health Regular tips about health Add as Preferred Source

Things worth knowing about "Atovaquone-Proguanil"

Atovaquone-proguanil is a combination medication used to prevent and treat malaria. It is commonly recommended for travelers visiting malaria-endemic regions.

What is Atovaquone-Proguanil?

Atovaquone-proguanil is a combination antimalarial drug containing two active ingredients: atovaquone and proguanil. It is used for both the prevention (prophylaxis) and treatment of uncomplicated falciparum malaria caused by the parasite Plasmodium falciparum. The medication is widely known under the brand name Malarone® and is one of the most commonly prescribed antimalarial agents for international travelers.

Indications

Atovaquone-proguanil is used in the following situations:

Malaria prophylaxis for travelers: Prevention of malaria infection when traveling to regions with known transmission risk, particularly in tropical and subtropical areas of Africa, Asia, and South America.
Treatment of uncomplicated falciparum malaria: Management of confirmed Plasmodium falciparum infection without severe complications.

Mechanism of Action

The two active components work synergistically by targeting different stages and pathways within the malaria parasite:

Atovaquone

Atovaquone disrupts the mitochondrial electron transport chain of Plasmodium falciparum by inhibiting Complex III (cytochrome bc1 complex). This blocks the parasite's ability to produce energy, ultimately leading to its death.

Proguanil

Proguanil is converted in the body to its active metabolite cycloguanil, which inhibits dihydrofolate reductase - an enzyme essential for folate synthesis in the parasite. In addition, proguanil independently potentiates the collapse of the mitochondrial membrane potential caused by atovaquone.

This dual mechanism of action makes the combination highly effective and significantly reduces the likelihood of drug resistance developing.

Dosage and Administration

Dosage depends on age, body weight, and the purpose of use (prophylaxis or treatment):

Prophylaxis (Prevention)

Begin taking the medication 1 to 2 days before entering the malaria-endemic area.
Take once daily throughout the entire stay.
Continue for 7 days after returning from the risk area.
Always take with food or a milky drink to improve absorption and reduce gastrointestinal side effects.

Treatment

In adults, the standard dose is typically 4 tablets once daily for 3 consecutive days.
In children, dosage is adjusted according to body weight.

Side Effects

Atovaquone-proguanil is generally well tolerated. Possible side effects include:

Common Side Effects

Headache
Nausea and vomiting
Abdominal pain or diarrhea
Dizziness

Rare Side Effects

Skin rash or itching
Elevated liver enzymes (transaminases)
Mouth ulcers
In very rare cases: allergic reactions

Individuals with known hypersensitivity to either active ingredient should not use this medication. Persistent or severe side effects should be evaluated by a healthcare professional.

Contraindications and Precautions

Severe renal impairment: Atovaquone-proguanil should not be used for prophylaxis in patients with severe kidney disease.
Pregnancy and breastfeeding: Use during pregnancy, particularly in the first trimester, and during breastfeeding is generally not recommended due to limited safety data. The decision should be made in consultation with a physician.
Children under 11 kg body weight: The medication is not approved for use in very young or small children.
Drug interactions: Concurrent use of rifampicin, tetracycline, or metoclopramide may reduce the effectiveness of atovaquone and should be avoided where possible.

Comparison with Other Antimalarials

Compared to other antimalarial medications such as mefloquine or doxycycline, atovaquone-proguanil offers several advantages:

Shorter post-travel dosing period (only 7 days after return, compared to 4 weeks with doxycycline or mefloquine).
Can be started just 1 to 2 days before travel, offering flexibility.
Favorable tolerability profile, especially the absence of neuropsychiatric side effects associated with mefloquine.

However, the cost of atovaquone-proguanil is generally higher than that of alternative prophylactic options. The choice of the most appropriate antimalarial should always be made in consultation with a travel medicine or tropical disease specialist.

References

World Health Organization (WHO): International Travel and Health. Geneva, updated edition. Available at: https://www.who.int/publications/i/item/9789240003088
Centers for Disease Control and Prevention (CDC): Malaria - Choosing a Drug to Prevent Malaria. Atlanta. Available at: https://www.cdc.gov/malaria/travelers/drugs.html
Overbosch D et al.: Atovaquone-Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers. Clinical Infectious Diseases, 33(7):1015-1021, 2001.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category

Pionier in Lactoferrin & naturbasierten Nutraceuticals seit 2016

150k Empfänger: Werde Teil der Community!

Wissenschaftliche Beiträge, Ernährungs- & Gesundheitstipps, sowie Zugang zu exklusiven Angeboten. Melde Dich an & sichere Dir 10% Nachlass auf Deinen nächsten Einkauf.